-- Introduces new panels for Parkinson’s disease, neuropathies, and
neuromuscular diseases --
-- Adds new genes to panels for arrhythmias, cardiomyopathies,
aortopathies, and congenital heart disease; introduces a new
cardiomyopathy and skeletal muscle disease panel --
SAN FRANCISCO--(BUSINESS WIRE)--
Invitae
Corporation (NYSE:
NVTA), a genetic information company, today announced that it has
expanded its neurology and cardiology test offering, adding 11 new
panels for heritable diseases. In addition, Invitae has updated 17
existing neurology panels and eight cardiology panels based on new
discoveries in genetics research.
With this latest expansion of its test offerings, Invitae will be able
to provide clinicians, patients, and payers with even higher-quality
information on genetic changes that have been shown to influence a
variety of neurologic and cardiovascular disorders – for the same price
and with the same three-week average turnaround time. The new panels
will be available immediately to children’s hospitals, pediatricians,
and medical genetics professionals for clinical diagnosis and care.
“Invitae is steadfast in its commitment to making high-quality genetic
tests based on the latest clinical and scientific evidence available to
patients and their family members,” said Robert Nussbaum, MD, chief
medical officer of Invitae. “The launch of our new and updated panels
clearly illustrates our ongoing dedication to careful and comprehensive
gene curation.”
Expanded neurology testing
With this expanded neurology offerings, Invitae provides clinicians,
patients, and payers with more options for high-quality, affordable
genetic testing, including:
-
Invitae’s
Hereditary Parkinson’s Disease & Parkinsonism Panel –
analyzing up to 17 genes associated with Parkinson’s disease and
related conditions involving Parkinsonian features
-
Invitae’s
Comprehensive Neuropathies Panel – 78 genes covering
Charcot-Marie-Tooth (CMT) disease, hereditary motor neuropathies,
hereditary sensory and autonomic neuropathy, and riboflavin
transporter deficiency neuronopathy
-
Invitae’s
Comprehensive Neuromuscular Disorders Panel – 116 genes covering
muscular dystrophy, myopathy, and congenital myasthenic syndrome
-
Additional myopathy panels, including a hyperkalemic periodic
paralysis test, a hypokalemic periodic paralysis panel, an inclusion
body myopathy panel, and an autophagic vacuolar myopathy panel
-
Additional neuropathy panels, including hereditary sensory and
autonomic neuropathy panels, a hereditary motor neuropathies panel,
and a riboflavin transporter deficiency neuronopathy panel
-
Updates to existing panels to incorporate the latest research findings:
"Genetic testing for hereditary Parkinson's disease has fundamentally
changed the way in which we look at providing answers to families
affected with this devastating condition," said J. William Langston, MD,
chief scientific officer and founder of the Parkinson's Institute and
Clinical Center. "My hope is for every person with early-onset
Parkinson's or a family history of the disease be provided the
opportunity to have genetic testing, so we can work together to develop
better treatments and improve healthcare for everyone."
Invitae’s latest expansion of its test offering is based on the latest
research findings in genetics across various panels. For example, three
peer-reviewed papers published in the past year show evidence that the
MORC2 gene causes CMT disease, and therefore was added to Invitae’s
comprehensive CMT panel:
“We are excited to see the addition of new genes in Invitae’s CMT
panel,” said Susan Ruediger, patient advocate and Director of
Development at the Charcot-Marie-Tooth Association (CMTA).
“Comprehensive genetic testing can provide patients with a definitive
diagnosis, which is critical for the treatment and management of the
disease.”
Cardiovascular panels aligned to new research
Understanding of the genetic links to cardiovascular disease is rapidly
advancing. Invitae has expanded eight existing cardiology panels to
reflect recent advances in the field to provide comprehensive,
evidence-based test options for diagnosing aortopathies, arrhythmias,
cardiomyopathies, and pulmonary hypertension. Additionally, Invitae has
added a new cardiomyopathy and skeletal muscle disease panel for
patients who exhibit overlapping features of both heart and skeletal
muscle disorders that analyzes up to 157 genes associated with
neuromuscular disorders and cardiomyopathies.
“The role of genetic testing in diagnosing cardiovascular disease is
rapidly expanding, now offering us insights that can help patients with
a variety of conditions, such as dilated cardiomyopathy and primary
arrhythmias,” said Ray Hershberger, MD, professor of cardiovascular
medicine and director of the division of human genetics at The Ohio
State University Wexner Medical Center. “Importantly, genetic testing
can also help us understand when cardiac problems are actually the first
symptoms of a broader genetic disease. Expanding our ability to access
clear and comprehensive genetic information will help us better diagnose
and treat patients.”
This expanded offering includes state-of-art cardiovascular genetic
testing with panels expertly curated and updated by medical and genetics
experts. The Invitae
Cardiomyopathy and Skeletal Muscle Disease Panel is a convenient and
economical option for patients presenting with overlapping features
associated with cardiomyopathies and muscular dystrophies that typically
require multiple test orders.
Affordable, transparent pricing
Invitae offers a transparent pricing structure independent of the number
of genes required to provide an accurate diagnosis within a single
clinical area. For payers and institutions that are in contract with
Invitae, the price per clinical area can be as low as $950, depending on
the payer’s requirements. For third-party payers with whom Invitae is
out-of-network and for non-contracted institutions, the price per
clinical area is $1,500. In addition, for patients without third-party
insurance coverage or who do not meet insurance criteria for coverage,
Invitae offers its full test offerings for $475 per clinical area (see website
for more details).
About Invitae
Invitae Corporation's (NYSE: NVTA) mission is to bring comprehensive
genetic information into mainstream medical practice to improve the
quality of healthcare for billions of people. Invitae’s goal is to
aggregate most of the world’s genetic tests into a single service with
higher quality, faster turnaround time, and lower price than many
single-gene and panel tests today. The company currently provides a
diagnostic service comprising hundreds of genes for a variety of genetic
disorders associated with oncology, cardiology, neurology, pediatrics,
and other rare disease areas. For more information, visit our website at invitae.com.
Safe Harbor Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including statements relating to the availability of the company’s new
panels; the effect of the company’s expansion of its test menu and its
ability to provide higher quality information on genetic changes; and
that such information will lead to better diagnoses and treatments for
patients. Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially, and
reported results should not be considered as an indication of future
performance. These risks and uncertainties include, but are not limited
to: risks associated with the company’s ability to use rapidly changing
genetic data to interpret test results accurately, consistently and
quickly; the company’s ability to develop and commercialize new tests
and expand into new markets; the company’s history of losses; the
company’s need to scale its infrastructure in advance of demand for its
tests and to increase demand for its tests; the risk that the company
may not obtain or maintain sufficient levels of reimbursement for its
tests; laws and regulations applicable to the company’s business,
including state licensing requirements and potential regulation by the
Food and Drug Administration; and the other risks set forth in the
company’s filings with the Securities and Exchange Commission, including
the risks set forth in the company’s Quarterly Report on Form 10-Q for
the quarter ended June 30, 2016. These forward-looking statements speak
only as of the date hereof, and Invitae Corporation disclaims any
obligation to update these forward-looking statements.
NOTE: Invitae and the Invitae logo are trademarks of Invitae
Corporation. All other trademarks and service marks are the property of
their respective owners.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160815005210/en/
Source: Invitae Corporation